Literature DB >> 25549229

Statins: definitive translational research.

Scott M Grundy1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25549229      PMCID： PMC4374515          DOI： 10.2119/molmed.2014.00194

Source DB:  PubMed          Journal:  Mol Med        ISSN： 1076-1551            Impact factor:   6.354


× No keyword cloud information.
  56 in total

1.  Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy.

Authors:  G L Vega; S M Grundy
Journal:  JAMA       Date:  1990-12-05       Impact factor: 56.272

2.  Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia.

Authors:  G L Vega; S M Grundy
Journal:  J Intern Med       Date:  1991-10       Impact factor: 8.989

3.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

4.  Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins.

Authors:  G L Vega; R M Krauss; S M Grundy
Journal:  J Intern Med       Date:  1990-02       Impact factor: 8.989

5.  Management of primary mixed hyperlipidemia with lovastatin.

Authors:  G L Vega; S M Grundy
Journal:  Arch Intern Med       Date:  1990-06

6.  Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia. Effects on kinetics of apolipoprotein B.

Authors:  G L Vega; C East; S M Grundy
Journal:  Arteriosclerosis       Date:  1989 Jan-Feb

7.  Metabolic basis of primary hypercholesterolemia.

Authors:  G L Vega; M A Denke; S M Grundy
Journal:  Circulation       Date:  1991-07       Impact factor: 29.690

8.  Effects of lovastatin on the levels, structure, and atherogenicity of VLDL in patients with moderate hypertriglyceridemia.

Authors:  S H Gianturco; W A Bradley; S Nozaki; G L Vega; S M Grundy
Journal:  Arterioscler Thromb       Date:  1993-04

9.  Coinheritance of two mild defects in low density lipoprotein receptor function produces severe hypercholesterolemia.

Authors:  R Uauy; G L Vega; S M Grundy
Journal:  J Clin Endocrinol Metab       Date:  1991-01       Impact factor: 5.958

Review 10.  Molecular genetics of the LDL receptor gene in familial hypercholesterolemia.

Authors:  H H Hobbs; M S Brown; J L Goldstein
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878
View more
  2 in total

1.  Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.

Authors:  Dick C Chan; Gerald F Watts; Ransi Somaratne; Scott M Wasserman; Rob Scott; P Hugh R Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-06-07       Impact factor: 8.311

2.  Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments?

Authors:  Qidi Ying; Annalisa Ronca; Dick C Chan; Jing Pang; Elda Favari; Gerald F Watts
Journal:  Eur J Clin Invest       Date:  2022-03-24       Impact factor: 5.722
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.